<!doctype html>																																																																																										<head><title>CG-LAB-32 Cancer Antigen 125 Testing</title><meta http-equiv="Content-Type" content="text/html; charset=utf-8"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="xUDType" content="Medical_Guideline"><meta name="file" content=""><meta name="UDCategory" content="LAB"><meta name="UDReference" content="CG-LAB-32"><meta name="UDType" content="Medical_Guideline"><meta name="UDStatus" content="Current"> <meta name="mpStatus" content="New"><meta name="title" content="CG-LAB-32"><meta name="xSortDate1" content="04/10/2024"><meta name="xSortPubTS" content="1712793599000"><meta name="date" content="04/10/2024"><link href="../../../css/cgmaster.css" rel="styleSheet" type="text/css" /><link href="../../../css/cgcommercial.css" rel="styleSheet" type="text/css" /> <script src="../../../js/adobeanalytics.js"></script>
<script>(window.BOOMR_mq=window.BOOMR_mq||[]).push(["addVar",{"rua.upush":"false","rua.cpush":"false","rua.upre":"false","rua.cpre":"false","rua.uprl":"false","rua.cprl":"false","rua.cprf":"false","rua.trans":"","rua.cook":"false","rua.ims":"false","rua.ufprl":"false","rua.cfprl":"false","rua.isuxp":"false","rua.texp":"norulematch"}]);</script>
                              <script>!function(a){var e="https://s.go-mpulse.net/boomerang/",t="addEventListener";if("True"=="True")a.BOOMR_config=a.BOOMR_config||{},a.BOOMR_config.PageParams=a.BOOMR_config.PageParams||{},a.BOOMR_config.PageParams.pci=!0,e="https://s2.go-mpulse.net/boomerang/";if(window.BOOMR_API_key="YDDHU-FFACC-3AYXK-XQKBX-62T4Z",function(){function n(e){a.BOOMR_onload=e&&e.timeStamp||(new Date).getTime()}if(!a.BOOMR||!a.BOOMR.version&&!a.BOOMR.snippetExecuted){a.BOOMR=a.BOOMR||{},a.BOOMR.snippetExecuted=!0;var i,_,o,r=document.createElement("iframe");if(a[t])a[t]("load",n,!1);else if(a.attachEvent)a.attachEvent("onload",n);r.src="javascript:void(0)",r.title="",r.role="presentation",(r.frameElement||r).style.cssText="width:0;height:0;border:0;display:none;",o=document.getElementsByTagName("script")[0],o.parentNode.insertBefore(r,o);try{_=r.contentWindow.document}catch(O){i=document.domain,r.src="javascript:var d=document.open();d.domain='"+i+"';void(0);",_=r.contentWindow.document}_.open()._l=function(){var a=this.createElement("script");if(i)this.domain=i;a.id="boomr-if-as",a.src=e+"YDDHU-FFACC-3AYXK-XQKBX-62T4Z",BOOMR_lstart=(new Date).getTime(),this.body.appendChild(a)},_.write("<bo"+'dy onload="document._l();">'),_.close()}}(),"".length>0)if(a&&"performance"in a&&a.performance&&"function"==typeof a.performance.setResourceTimingBufferSize)a.performance.setResourceTimingBufferSize();!function(){if(BOOMR=a.BOOMR||{},BOOMR.plugins=BOOMR.plugins||{},!BOOMR.plugins.AK){var e=""=="true"?1:0,t="",n="wzdhuyixgvbdiztzh7pa-f-f0f3d5301-clientnsv4-s.akamaihd.net",i="false"=="true"?2:1,_={"ak.v":"37","ak.cp":"202149","ak.ai":parseInt("244874",10),"ak.ol":"0","ak.cr":41,"ak.ipv":4,"ak.proto":"http/1.1","ak.rid":"7ef8d98","ak.r":36095,"ak.a2":e,"ak.m":"a","ak.n":"essl","ak.bpcip":"182.70.122.0","ak.cport":51734,"ak.gh":"23.210.93.87","ak.quicv":"","ak.tlsv":"tls1.3","ak.0rtt":"","ak.csrc":"-","ak.acc":"reno","ak.t":"1719222238","ak.ak":"hOBiQwZUYzCg5VSAfCLimQ==bvYvEK2ww1CPRfihVbpaZfBWjKXhhGIVPdK3wbjVuKocqJDIqQT0bsPxvZBACQO3ekTAN7NIi6wBJS7WCXK8F8C1iKMurruK260hhEUREsOdkkC9lprc3R/E9q0ohWZabV182osEbApIrroPKKIF+MPcaCuKRBOiUo8q1ZJnAQO3XRUc6geHedcY/bgwwzhAmkuWIIF3BEh9qrM4OzsvDcrV79FDJN+HqHyI2TI5dCrC1L/GdHrIAkta/zTi5VGwc8LuhDRT0W7s2c6cVXOA0ECyRCixkIb6zl5LOr1dGIBFePrOwt9z6aS+3inKKQKhbKXVRx05wsX29DOuApVowK7y2+yQ39/Q8wVY8x/m/REGZyPQnoW/oAbkfuJd9Cku6r5dtnZIb5x3Fys1hiEJheLFfgryqV/y/NyBE6QmK+A=","ak.pv":"490","ak.dpoabenc":"","ak.tf":i};if(""!==t)_["ak.ruds"]=t;var o={i:!1,av:function(e){var t="http.initiator";if(e&&(!e[t]||"spa_hard"===e[t]))_["ak.feo"]=void 0!==a.aFeoApplied?1:0,BOOMR.addVar(_)},rv:function(){var a=["ak.bpcip","ak.cport","ak.cr","ak.csrc","ak.gh","ak.ipv","ak.m","ak.n","ak.ol","ak.proto","ak.quicv","ak.tlsv","ak.0rtt","ak.r","ak.acc","ak.t","ak.tf"];BOOMR.removeVar(a)}};BOOMR.plugins.AK={akVars:_,akDNSPreFetchDomain:n,init:function(){if(!o.i){var a=BOOMR.subscribe;a("before_beacon",o.av,null,null),a("onbeacon",o.rv,null,null),o.i=!0}return this},is_complete:function(){return!0}}}}()}(window);</script><script >bazadebezolkohpepadr="1885181968"</script><script type="text/javascript" src="https://www.anthem.com/akam/13/705d9972"  defer></script></head><body><table> <tbody> <tr> <td><img class="logo_abc" src="../../images/abc.svg" /></td> <td id="policyTypeHeading">Clinical UM Guideline</td> </tr> </tbody> </table> <table id="docDetails"> <tbody> <tr> <td colspan="2"><strong>Subject:</strong> Cancer Antigen 125 Testing</td> </tr> <tr> <td width="75%"><strong>Guideline #:</strong> CG-LAB-32</td> <td><strong>Publish Date:</strong> 04/10/2024</td> </tr> <tr> <td width="75%"><strong>Status:</strong> New</td> <td><strong>Last Review Date:</strong> 02/15/2024</td> </tr> </tbody> </table>  <table border="1" cellpadding="0" cellspacing="0" style="width:100%">	<tbody>		<tr>			<td class="head_stripe" width="100%"><strong>Description</strong></td>		</tr>	</tbody></table><p>This document addresses the tumor marker cancer antigen 125 (CA-125) testing.</p><table border="1" cellpadding="0" cellspacing="0" style="height:21px; width:100%">	<tbody>		<tr>			<td class="head_stripe" height="21" width="100%"><strong>Clinical Indications</strong></td>		</tr>	</tbody></table><p><strong>Medically</strong><strong> Necessary:</strong></p><p>CA-125 testing is considered <strong>medically necessary</strong> for any of the following:</p><ol>	<li>Suspected ovarian cancer:	<ol style="list-style-type:lower-alpha">		<li>Evaluation of a pelvic or abdominal mass in postmenopausal individuals; <strong>or</strong></li>		<li>Evaluation of a pelvic or abdominal mass suspicious for an epithelial ovarian cancer or other specified malignancy in premenopausal individuals; <strong>or</strong></li>		<li>Evaluation of an individual with signs or symptoms suggestive of ovarian cancer (for example, ascites, abdominal distention, bloating, pelvic/abdominal pain, difficulty eating or feeling full quickly, urinary symptoms); <strong>or</strong></li>	</ol>	</li>	<li>Management of ovarian cancer:	<ol style="list-style-type:lower-alpha">		<li>As an aid in the monitoring of disease; <strong>or</strong></li>		<li>Assessing response to treatment: <strong>or</strong></li>		<li>As an aid to a surgical procedure; <strong>or</strong></li>		<li>Detection of recurrent disease; <strong>or</strong></li>	</ol>	</li>	<li>Management of endometrial cancer:	<ol style="list-style-type:lower-alpha">		<li>As an aid to a surgical procedure; <strong>or</strong></li>		<li>When elevated at diagnosis, to be used as an aid in the monitoring of disease, assessment of response to treatment and monitoring for recurrent disease; <strong>or</strong></li>	</ol>	</li>	<li>Surveillance in individuals with hereditary breast and ovarian cancer syndrome starting at age 30 years until the time they choose to pursue risk-reducing bilateral salpingo-oophorectomy; <strong>or</strong></li>	<li>Evaluation or management of the following malignancies:	<ol style="list-style-type:lower-alpha">		<li>Appendiceal adenocarcinoma; <strong>or</strong></li>		<li>Pancreatic adenocarcinoma; <strong>or</strong></li>		<li>Peritoneal mesothelioma; <strong>or</strong></li>		<li>Uterine neoplasms.</li>	</ol>	</li></ol><p><strong>Not Medically Necessary:</strong></p><p>CA-125 testing is considered <strong>not medically necessary</strong> when the above criteria are not met.</p><table border="1" cellpadding="0" cellspacing="0" style="width:100%">	<tbody>		<tr>			<td class="head_stripe" width="100%"><strong>Coding</strong></td>		</tr>	</tbody></table><p><em>The following codes for treatments and procedures applicable to this guideline are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member&#39;s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.</em></p><p><strong>When services are Medically Necessary:</strong></p><table cellspacing="0" class="Table" style="border-collapse:collapse; margin-left:15px; width:682px">	<tbody>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p style="text-align:justify"><strong>CPT</strong></p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>&nbsp;</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p style="text-align:justify">86304</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Immunoassay for tumor antigen, quantitative; CA 125</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>&nbsp;</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>&nbsp;</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p><strong>ICD-10 Diagnosis</strong></p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>&nbsp;</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>C18.1</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Malignant neoplasm of appendix</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>C25.0-C25.9</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Malignant neoplasm of pancreas</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>C45.1</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Mesothelioma of peritoneum</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>C48.0-C48.8</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Malignant neoplasm of retroperitoneum and peritoneum</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>C51.8</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Malignant neoplasm of overlapping sites of vulva</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>C53.0-C55</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Malignant neoplasm of cervix uteri, corpus uteri, uterus part unspecified</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>C56.1-C56.9</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Malignant neoplasm of ovary</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>C57.00-C57.9</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Malignant neoplasm of other and unspecified female genital organs</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>C7B.04</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Secondary carcinoid tumors of peritoneum</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>C76.2-C76.3</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Malignant neoplasm of abdomen, pelvis</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>C78.6</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Secondary malignant neoplasm of retroperitoneum and peritoneum</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>C79.60-C79.63</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Secondary malignant neoplasm of ovary</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>C79.82</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Secondary malignant neoplasm of genital organs</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>D07.0-D07.39</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Carcinoma in situ of endometrium, vulva, vagina, other and unspecified female genital organs</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>D25.0-D26.9</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Leiomyoma of uterus, other benign neoplasms of uterus</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>D27.0-D27.9</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Benign neoplasm of ovary</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>D39.0-D39.9</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Neoplasm of uncertain behavior of female genital organs</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>D48.114</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Desmoid tumor, intraabdominal</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>D48.3-D48.4</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Neoplasm of uncertain behavior of retroperitoneum, peritoneum</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>D49.59</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Neoplasm of unspecified behavior of other genitourinary organ</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>G89.3</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Neoplasm related pain (acute) (chronic)</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>M33.00-M33.99</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Dermatopolymyositis</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>N32.81</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Overactive bladder</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>N39.41-N39.498</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Other specified urinary incontinence</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>N73.0-N73.9</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Other female pelvic inflammatory diseases</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>N80.00-N80.399</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Endometriosis of uterus, ovary, fallopian tube, pelvic peritoneum</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>R10.0-R10.9</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Abdominal and pelvic pain</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>R14.0</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Abdominal distension (gaseous)</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>R18.0-R18.8</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Ascites</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>R19.00-R19.09</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Intra-abdominal and pelvic swelling, mass and lump</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>R32</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Unspecified urinary incontinence</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>R35.0-R35.89</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Polyuria</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>R39.15</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Urgency of urination</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>R63.30-R63.39</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Feeding difficulties</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>R68.81</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Early satiety</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>R97.0-R97.1</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Elevated carcinoembryonic antigen [CEA], elevated cancer antigen 125 [CA 125]</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>R97.8</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Other abnormal tumor markers</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>Z15.01-Z15.02</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Genetic susceptibility to malignant neoplasm of breast, ovary</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>Z85.41-Z85.44</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Personal history of malignant neoplasm of cervix uteri, other parts of uterus, ovary, other female genital organs</p>			</td>		</tr>	</tbody></table><p><strong>When services are Not Medically Necessary:</strong><br />For the procedure codes listed above for all other diagnoses not listed.</p><table border="1" cellpadding="0" cellspacing="0" style="width:100%">	<tbody>		<tr>			<td class="head_stripe" width="100%"><strong>Discussion/General Information</strong></td>		</tr>	</tbody></table><p>Cancer antigen 125 (CA-125) is a type of tumor marker. It is commonly expressed by epithelial ovarian neoplasms and other tissues, such as cells lining the endometrium, fallopian tubes, pleura, peritoneum, and pericardium. High levels of tumor markers such as CA-125 in the blood may also be a sign of cancer. CA-125 testing may be used to monitor how well cancer treatments are working or if cancer has reoccurred. However, elevated levels of CA-125 may also be present in instances of endometriosis, pregnancy, pelvic inflammatory disease, and nongynecologic cancer. These instances of potential fluctuation in CA-125 levels can lead to false positive results and limited specificity.</p><p><em>Ovarian Cancer</em><br />The National Comprehensive Cancer Network<sup>&reg; </sup>(NCCN) guidelines for Ovarian Cancer including Fallopian Tube Cancer and Primary Peritoneal Cancer (NCCN, 2024) recommend CA-125 testing for those who present with a suspicious or palpable pelvic mass on abdominal/pelvic exam, and/or ascites, or abdominal distention. The NCCN also recommends CA-125 testing for those with symptoms not without source of malignancy (that is, bloating, pelvic/abdominal pain, difficulty eating or feeling full quickly, and urinary symptoms [urgency or frequency]). In addition, the NCCN guidelines recommend CA-125 testing for individuals with a new diagnosis of ovarian cancer after a recent surgical procedure and as part of a preoperative workup. This is based on data showing that CA-125 levels correlate with the extent of the disease, the clinical course of the disease which can assist in treatment planning, monitoring response to therapy, and surveillance for recurrence. The NCCN guideline also notes &ldquo;Primary peritoneal and fallopian tube cancers are treated in the same manner as epithelial ovarian cancer.&rdquo;</p><p>The 2016 American College of Obstetricians and Gynecologists (ACOG) practice bulletin for evaluation and management of adnexal masses states that using CA-125 in the evaluation of adnexal masses is most useful in those who are postmenopausal and in identifying nonmucinous epithelial cancer. For those with epithelial ovarian cancer, the CA-125 level is elevated in 80% of individuals.</p><p>Surveillance of ovarian cancer, including concurrent transvaginal ultrasound (TVUS) and testing of CA-125, may be appropriate for certain high-risk individuals (specifically, carriers of high penetrance hereditary breast and ovarian cancer syndrome-associated mutations with a strong family history of breast and ovarian cancer) who are of the age range of recommended risk-reducing salpingo-oophorectomy and opt not to pursue it. Studies of concurrent testing with CA-125 and TVUS in high-risk individuals are largely limited to observational studies and have found that most detected cancers (70 to 80 percent) are stage III or IV, with a positive predictive value of 26% for incident screening. The 2024 NCCN guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic along with the American Cancer Society and ACOG suggest that screening may be appropriate in individuals with a diagnosed genetic syndrome that increases the lifetime risk for ovarian and breast cancer and have not or not yet elected to pursue risk-reducing removal of bilateral tubes/ovaries.</p><p>Neither current literature nor the United States Preventive Services Task Force (USPSTF) support routine screening for ovarian cancer in asymptomatic individuals. The 2017 ACOG committee opinion titled &ldquo;The Role of the Obstetrician&ndash;Gynecologist in the Early Detection of Epithelial Ovarian Cancer in Women at Average Risk&rdquo; concludes:</p><p style="margin-left:40px; margin-right:46px">The use of transvaginal ultrasonography and tumor markers (such as CA 125), alone or in combination, for the early detection of ovarian cancer in average-risk women have not been proved to reduce mortality, and harms exist from invasive diagnostic testing (eg, surgery) resulting from false-positive test results.</p><p>In 2016, Pinsky and colleagues reported an analysis of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial with extended mortality follow-up for 6 years. Those in the intervention arm were screened for ovarian cancer with annual trans-vaginal ultrasound and CA-125. There was a total of 187 deaths from ovarian cancer in the intervention arm and 176 deaths in the usual care arm, for a risk-ratio of 1.06 (95% confidence interval [CI], 0.87&ndash;1.30). The authors concluded there was no mortality benefit from screening for ovarian cancer with CA-125 and transvaginal ultrasound.</p><p>A 1996 prospective study by Jacobs and colleagues analyzed the risk of epithelial ovarian cancer and fallopian tube cancer in asymptomatic, postmenopausal individuals with an elevated CA-125. The authors concluded that an elevated CA-125 was a predictor of ovarian cancer with a relative risk of 35.9 (95% CI, 18.3 to 70.4) during the year after a screen and 14.3 (8.5 to 24.3) during the 5 years after a screen. However, in 2009 Partridge and colleagues (as part of the PLCO Cancer Screening Trial) reported whether annual screening with transvaginal ultrasound and CA-125 reduces ovarian cancer mortality. The authors found &ldquo;the surgery to detected cancer ratio was 19.5 to 1, and 72% of screen detected cancers were late stage.&rdquo;</p><p>Individuals who are premenopausal have a higher likelihood of having benign gynecologic conditions. However, positive predictive value (PPV) is low even in those who are postmenopausal. In the detection of ovarian cancer in postmenopausal individuals, specificity of a single CA-125 ranged from 98.6% to 99.4% which resulted in a low PPV of 3% (Einhorn, 1992; Zurawski, 1988). PPV for invasive cancer among healthy women ages 55 to 74 years old was similarly low.</p><p>Screening for ovarian cancer can be challenging due to the low disease prevalence in those at average risk. Testing strategies should include those with high specificity and sensitivity to minimize false-positive tests. Screening for those at average risk with CA-125 has not been shown to reduce mortality.</p><p><em>Endometrial Cancer</em><br />Along with expert review, the 2024 NCCN guideline for Uterine Neoplasms considers CA-125 in the initial evaluation of endometrial cancer and as an aid to a surgical procedure.</p><p>A single-center retrospective chart review by LyBarger and colleagues in 2022 reported the odds ratio (OR) and relative risks (RR) between preoperative levels of CA-125 and the likelihood of a positive (+) lymph node metastasis and + lymphovascular space invasion. Using preoperative levels of CA-125, risk factors for + lymph node metastasis could distinguish those who are more likely to benefit from lymphadenectomy versus those who would not. There were 890 participants included. There was an increase in the median CA-125 and for those with + lymph node metastasis and + lymphovascular space invasion. Also, as stage and grade of disease increased, CA-125 generally increased. The RR and OR tended to increase above a CA-125 threshold of 35U/ml for all participants. The participants who had a CA-125 level of 9U/ml, 10U/ml, or 12U/ml had a decrease in risk of +lymph node metastasis 87, 88, and 72% respectively. With a CA-125 level of 222U/ml or greater, the largest increase in risk for participants having stage II/III/IV disease was 52% greater than for stage I and the largest risk for those having stage III/IV disease was 66% greater. Participants with a CA-125 of 122U/ml or greater showed a significantly increased risk of +lymph node metastasis and those with a CA-125 of 199 U/ml or greater showed a significantly increased risk of + lymphovascular space invasion. The authors concluded an elevated preoperative CA125 is associated with an increased risk of elevated stage, + lymphovascular space invasion, +lymph node metastasis, and higher grade, which could be associated with less favorable outcomes.</p><p><em>Hereditary Breast and Ovarian Cancer</em><br />The 2024 NCCN guideline for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic notes that for individuals diagnosed with a genetic syndrome that increases the lifetime risk for ovarian and breast cancer and have not or not yet elected to pursue risk-reducing removal of bilateral tubes/ovaries, CA-125 results using the risk of ovarian cancer algorithm (ROCA) protocol in high-risk individuals suggest a stage shift. Conclusions were based on a study of 4348 individuals with an estimated lifetime ovarian cancer risk no less than 10% who underwent ovarian cancer screening via serum CA-125 tests every 4 months (using ROCA protocol). There were 13 participants who were diagnosed with ovarian cancer as a result of the screening protocol, with 5 of the 13 participants being diagnosed with early-stage cancer. The sensitivity, positive predictive value, and negative predictive value of the screening protocol for detecting ovarian cancer within 1 year were 94.7%, 10.8%, and 100%, respectively.</p><p>The 2017 ACOG Practice Bulletin for Hereditary Breast and Ovarian Cancer Syndrome (ACOG, 2017) states:</p><p style="margin-left:40px">In women with BRCA mutations or who have a personal or family history of ovarian cancer, routine ovarian cancer screening with measurement of serum CA 125 level or transvaginal ultrasonography generally is not recommended. Transvaginal ultrasonography or measurement of serum CA 125 level may be reasonable for short-term surveillance in women at high risk of ovarian cancer starting at age 30&ndash;35 years until the time they choose to pursue risk-reducing bilateral salpingo-oophorectomy.</p><p><em>Other Malignancies</em><br />Appendiceal cancer is very rare. For those with appendiceal adenocarcinoma, the 2023 NCCN guideline for Colon Cancer recommends CA-125 levels, particularly if CEA and CA 19-9 levels are normal. Also noting that normal CA-125 and CA19-9 levels correspond to an increase in survival and a decrease in recurrence of disease.</p><p>Expert review indicates CA-125 results can be clinically relevant in pancreatic adenocarcinoma, appendiceal adenocarcinoma, peritoneal mesothelioma and uterine neoplasms. The NCCN guideline for Pancreatic Adenocarcinoma notes that for resectable disease, neoadjuvant therapy, borderline resectable disease without metastases, and postoperative adjuvant treatment, CA-125 can be used in individuals who are nonsecreting or in those with normal CA 19-9 levels.</p><p>Peritoneal mesothelioma is a rare form of cancer that affects the peritoneum (the membrane that lines the abdominal cavity and organs). The use of paracentesis fluid (cytology) is not recommended for diagnosis as invasion can&rsquo;t be detected using cytology. The 2024 NCCN guidelines for Mesothelial: Peritoneal recommends CA-125 could be considered for the initial evaluation of peritoneal mesothelial.</p><p>In the evaluation of uterine neoplasms, the 2024 NCCN guideline recommends CA-125 in the initial preoperative evaluation for known or suspected malignancy, suspected extrauterine disease, and in surveillance of disease if the initial CA-125 was elevated. For those with extrauterine disease, CA-125 levels may be helpful to monitor clinical response. In addition, individuals with uterine serous carcinoma, clear cell carcinoma, carcinosarcoma, or undifferentiated/dedifferentiated carcinomas may present with pelvic masses, abnormal cervical cytology, or ascites in addition to postmenopausal bleeding. The NCCN also recommends CA-125 may be useful prior to surgery to assess if extrauterine disease is present.</p><table border="1" cellpadding="0" cellspacing="0" style="height:-5; width:100%">	<tbody>		<tr>			<td class="head_stripe" height="-5" width="100%"><strong>Definitions</strong></td>		</tr>	</tbody></table><p>Ascites: The accumulation of fluid in spaces within the abdomen.</p><table border="1" cellpadding="0" cellspacing="0" style="width:100%">	<tbody>		<tr>			<td class="head_stripe" width="100%"><strong>References</strong></td>		</tr>	</tbody></table><p><strong>Peer Reviewed Publications:</strong></p><ol>	<li>Buys S, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. JAMA. 2011; 305(22):2295-2303.</li>	<li>Einhorn N, Sj&ouml;vall K, Knapp RC, et al. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol. 1992; 80(1):14-18.</li>	<li>Jacobs IJ, Skates S, Davies AP, et al. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. BMJ. 1996; 313(7069):1355-1358.</li>	<li>Johnson CC, Kessel B, Riley TL, et al. The epidemiology of CA-125 in women without evidence of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. Gynecol Oncol. 2008; 110(3):383-389.</li>	<li>LyBarger K, Miller HA, Frieboes HB, et al. CA125 as a predictor of endometrial cancer lymphovascular space invasion and lymph node metastasis for risk stratification in the preoperative setting. Sci Rep. 2022; 12(1):19783.</li>	<li>Partridge E, Kreimer AR, Greenlee RT, et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol. 2009; 113(4):775-782.</li>	<li>Pinsky P, Yu K, Kramer B, et al. Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up. Gynecol Oncol. 2016; 143(2):270-275.</li>	<li>Zurawski VR, Orjaseter H, Anderson A, et al. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int J Cancer. 1988; 42(5):677-680.</li></ol><p><strong>Government Agency, Medical Society, and Other Authoritative Publications:</strong></p><ol>	<li>ACOG Committee Opinion Number 716: The role of the obstetrician&ndash;gynecologist in the early detection of epithelial ovarian cancer in women at average risk. Obstet Gynecol. 2017; 130(3):e146-e149.</li>	<li>ACOG Practice Bulletin No. 174: Evaluation and management of adnexal masses. Obstet Gynecol. 2016; 128(5):e210-e226.</li>	<li>ACOG Practice Bulletin No. 182: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol. 2017; 130(3):e110-e126.</li>	<li>NCCN Clinical Practice Guidelines in Oncology<sup>&reg;</sup>. &copy; 2023 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: http://www.nccn.org/index.asp. Accessed on November 14, 2023.	<ul style="list-style-type:disc">		<li>Colon Cancer (V4.2023). Revised November 16, 2023.</li>		<li>Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic (V2.2024) Revised September 27, 2023.</li>		<li>Mesothelial: Peritoneal (V1.2024). Revised November 21, 2023.</li>		<li>Ovarian Cancer including Fallopian Tube Cancer and Primary Peritoneal Cancer (V1.2024) Revised January 17, 2024.</li>		<li>Pancreatic Adenocarcinoma (V1.2024). Revised December 13, 2023.</li>		<li>Uterine Neoplasms (V1.2024). Revised September 20, 2023.</li>	</ul>	</li></ol><table border="1" cellpadding="0" cellspacing="0" style="width:100%">	<tbody>		<tr>			<td class="head_stripe" width="100%"><strong>Websites for Additional Information</strong></td>		</tr>	</tbody></table><ol>	<li>American Cancer Society. Ovarian cancer. Available at: <a href="https://www.cancer.org/cancer/types/ovarian-cancer.html" style="color:blue; text-decoration:underline">https://www.cancer.org/cancer/types/ovarian-cancer.html</a>. Accessed on January 18, 2024.</li>	<li>United States Preventive Services Task Force. Recommendation: Ovarian cancer. 2018. Available at: <a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/ovarian-cancer-screening" style="color:blue; text-decoration:underline">https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/ovarian-cancer-screening</a>. Accessed on November 14, 2023.</li></ol><table border="1" cellpadding="0" cellspacing="0" style="width:100%">	<tbody>		<tr>			<td class="head_stripe" width="100%"><strong>Index</strong></td>		</tr>	</tbody></table><p>CA-125</p><table border="1" cellpadding="0" cellspacing="0" style="width:100%">	<tbody>		<tr>			<td class="head_stripe" width="100%"><strong>History</strong></td>		</tr>	</tbody></table><table cellspacing="0" class="Table" style="border-collapse:collapse; margin-left:7px; width:682px">	<tbody>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:90px">			<p><strong>Status</strong></p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:101px">			<p><strong>Date</strong></p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:491px">			<p><strong>Action</strong></p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:90px">			<p>New</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:101px">			<p>02/15/2024</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:491px">			<p>Medical Policy &amp; Technology Assessment Committee (MPTAC) review. Initial document development.</p>			</td>		</tr>	</tbody></table><hr /><p>Federal and State law, as well as contract language, and Medical Policy take precedence over Clinical UM Guidelines. We reserve the right to review and update Clinical UM Guidelines periodically. Clinical guidelines approved by the Medical Policy &amp; Technology Assessment Committee are available for general adoption by plans or lines of business for consistent review of the medical necessity of services related to the clinical guideline when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether to adopt a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the member&#39;s card.</p><p>Alternatively, commercial or FEP plans or lines of business which determine there is not a need to adopt the guideline to review services generally across all providers delivering services to Plan&rsquo;s or line of business&rsquo;s members may instead use the clinical guideline for provider education and/or to review the medical necessity of services for any provider who has been notified that his/her/its claims will be reviewed for medical necessity due to billing practices or claims that are not consistent with other providers, in terms of frequency or in some other manner.</p><p>No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.</p><p>&copy; CPT Only - American Medical Association</p><noscript><img src="https://www.anthem.com/akam/13/pixel_705d9972?a=dD02ZDg4OGQ2YzM5NmU3NGQxMjQzMmRjOTNjOGJlMzhmZWQxZmI0Zjc0JmpzPW9mZg==" style="visibility: hidden; position: absolute; left: -999px; top: -999px;" /></noscript><script type="text/javascript"  src="/iOP-/eY9D/A/kZ/IVzY-qg/OuYDVXwhtJ/aioOJQUXBw/JwpDFiM/2Xh4"></script></body>			</html>